The Clinical Significance of Serum Biomarkers of the Intestinal Barrier in Systemic Sclerosis: A Cross-Sectional Study
Systemic sclerosis (SSc) is an immune-mediated connective tissue disease. Recent studies reported differences in the composition of intestinal microbiota (dysbiosis) in patients with SSc compared to nonsclerodermic subjects. Dysbiosis may disrupt the intestinal barrier, which leads to immunological...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/13/4/678 |
| _version_ | 1797604767069896704 |
|---|---|
| author | Albert Stec Magdalena Maciejewska Michał Zaremba Karolina Paralusz-Stec Milena Michalska Lidia Rudnicka Mariusz Sikora |
| author_facet | Albert Stec Magdalena Maciejewska Michał Zaremba Karolina Paralusz-Stec Milena Michalska Lidia Rudnicka Mariusz Sikora |
| author_sort | Albert Stec |
| collection | DOAJ |
| description | Systemic sclerosis (SSc) is an immune-mediated connective tissue disease. Recent studies reported differences in the composition of intestinal microbiota (dysbiosis) in patients with SSc compared to nonsclerodermic subjects. Dysbiosis may disrupt the intestinal barrier, which leads to immunological activation via microbial antigen and metabolite translocation. The study aimed to assess the differences in intestinal permeability between SSc patients and controls and to examine the correlation between intestinal permeability and complications of SSc. The study comprised 50 patients with SSc and 30 matched subjects. Serum intestinal permeability markers: intestinal fatty acid binding protein, claudin-3, and lipopolysaccharides (LPS) were determined using an enzyme-linked immunosorbent assay. SSc patients had a significantly increased concentration of LPS compared to control subjects (232.30 [149.00–347.70] versus 161.00 [83.92–252.20] pg/mL, <i>p</i> < 0.05). The patients with shorter SSc duration (≤6 years) had an increased concentration of LPS and claudin-3 compared to the subgroup with longer disease length: LPS (280.75 [167.30–403.40] versus 186.00 [98.12–275.90] pg/mL, <i>p</i> < 0.05), and claudin-3 (16.99 [12.41–39.59] versus 13.54 [10.29–15.47] ng/mL, <i>p</i> < 0.05). The patients with esophageal dysmotility had a decreased LPS level compared to those without this complication (188.05 [102.31–264.40] versus 283.95 [203.20–356.30] pg/mL, <i>p</i> < 0.05). Increased intestinal permeability in SSc may exacerbate the course of the disease and increase the risk of developing complications. Lower LPS levels in SSc might be a hallmark of esophageal dysmotility. |
| first_indexed | 2024-03-11T04:51:25Z |
| format | Article |
| id | doaj.art-d6aaa87830624998bbbec1726e8fc661 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-11T04:51:25Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-d6aaa87830624998bbbec1726e8fc6612023-11-17T20:00:36ZengMDPI AGJournal of Personalized Medicine2075-44262023-04-0113467810.3390/jpm13040678The Clinical Significance of Serum Biomarkers of the Intestinal Barrier in Systemic Sclerosis: A Cross-Sectional StudyAlbert Stec0Magdalena Maciejewska1Michał Zaremba2Karolina Paralusz-Stec3Milena Michalska4Lidia Rudnicka5Mariusz Sikora6Department of Dermatology, Medical University of Warsaw, Koszykowa 82A, 02-008 Warsaw, PolandDepartment of Dermatology, Medical University of Warsaw, Koszykowa 82A, 02-008 Warsaw, PolandDepartment of Dermatology, Medical University of Warsaw, Koszykowa 82A, 02-008 Warsaw, PolandDepartment of Dermatology, Medical University of Warsaw, Koszykowa 82A, 02-008 Warsaw, PolandDepartment of General, Vascular and Transplant Surgery, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, PolandDepartment of Dermatology, Medical University of Warsaw, Koszykowa 82A, 02-008 Warsaw, PolandNational Institute of Geriatrics, Rheumatology and Rehabilitation, Spartańska 1, 02-637 Warsaw, PolandSystemic sclerosis (SSc) is an immune-mediated connective tissue disease. Recent studies reported differences in the composition of intestinal microbiota (dysbiosis) in patients with SSc compared to nonsclerodermic subjects. Dysbiosis may disrupt the intestinal barrier, which leads to immunological activation via microbial antigen and metabolite translocation. The study aimed to assess the differences in intestinal permeability between SSc patients and controls and to examine the correlation between intestinal permeability and complications of SSc. The study comprised 50 patients with SSc and 30 matched subjects. Serum intestinal permeability markers: intestinal fatty acid binding protein, claudin-3, and lipopolysaccharides (LPS) were determined using an enzyme-linked immunosorbent assay. SSc patients had a significantly increased concentration of LPS compared to control subjects (232.30 [149.00–347.70] versus 161.00 [83.92–252.20] pg/mL, <i>p</i> < 0.05). The patients with shorter SSc duration (≤6 years) had an increased concentration of LPS and claudin-3 compared to the subgroup with longer disease length: LPS (280.75 [167.30–403.40] versus 186.00 [98.12–275.90] pg/mL, <i>p</i> < 0.05), and claudin-3 (16.99 [12.41–39.59] versus 13.54 [10.29–15.47] ng/mL, <i>p</i> < 0.05). The patients with esophageal dysmotility had a decreased LPS level compared to those without this complication (188.05 [102.31–264.40] versus 283.95 [203.20–356.30] pg/mL, <i>p</i> < 0.05). Increased intestinal permeability in SSc may exacerbate the course of the disease and increase the risk of developing complications. Lower LPS levels in SSc might be a hallmark of esophageal dysmotility.https://www.mdpi.com/2075-4426/13/4/678systemic sclerosismicrobiotagut–skin axisdysbiosisinflammationimmune-mediated inflammatory diseases |
| spellingShingle | Albert Stec Magdalena Maciejewska Michał Zaremba Karolina Paralusz-Stec Milena Michalska Lidia Rudnicka Mariusz Sikora The Clinical Significance of Serum Biomarkers of the Intestinal Barrier in Systemic Sclerosis: A Cross-Sectional Study Journal of Personalized Medicine systemic sclerosis microbiota gut–skin axis dysbiosis inflammation immune-mediated inflammatory diseases |
| title | The Clinical Significance of Serum Biomarkers of the Intestinal Barrier in Systemic Sclerosis: A Cross-Sectional Study |
| title_full | The Clinical Significance of Serum Biomarkers of the Intestinal Barrier in Systemic Sclerosis: A Cross-Sectional Study |
| title_fullStr | The Clinical Significance of Serum Biomarkers of the Intestinal Barrier in Systemic Sclerosis: A Cross-Sectional Study |
| title_full_unstemmed | The Clinical Significance of Serum Biomarkers of the Intestinal Barrier in Systemic Sclerosis: A Cross-Sectional Study |
| title_short | The Clinical Significance of Serum Biomarkers of the Intestinal Barrier in Systemic Sclerosis: A Cross-Sectional Study |
| title_sort | clinical significance of serum biomarkers of the intestinal barrier in systemic sclerosis a cross sectional study |
| topic | systemic sclerosis microbiota gut–skin axis dysbiosis inflammation immune-mediated inflammatory diseases |
| url | https://www.mdpi.com/2075-4426/13/4/678 |
| work_keys_str_mv | AT albertstec theclinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy AT magdalenamaciejewska theclinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy AT michałzaremba theclinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy AT karolinaparaluszstec theclinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy AT milenamichalska theclinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy AT lidiarudnicka theclinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy AT mariuszsikora theclinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy AT albertstec clinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy AT magdalenamaciejewska clinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy AT michałzaremba clinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy AT karolinaparaluszstec clinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy AT milenamichalska clinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy AT lidiarudnicka clinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy AT mariuszsikora clinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy |